Abstract Library

#4389 The LOLA trial: Phase II trial with combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumours (NETs) – Interim results of step 1

Introduction: LOLA is an Italian, multicentre, open-label, double cohort, non-randomised, 3-stage, phase 2 trial aiming to assess the safety and activity of the combination of cabozantinib (CABO) + lanreotide (LAN) in patients (pts) with advanced or metastatic GEP and unknown primary NETs with Ki-67 > 10% or thoracic NET. In NETs sunitinib is the only TKI approved in advanced pancreatic NETs. While CABO has been reported superior to sunitinib in renal cancer its role in NETs is still investigational.

Conference:

Presenting Author: Oldani S

Authors: Oldani S, Morano F, Brizzi M, Giuffrida D, Panzuto F,

Keywords: gastroenteropancreatic neuroendocrine tumour, cabozantinib, lanreotide, clinical trial,

#3032 Lung Side and Site: The Importance of Location and the Prognostic Implication in Lung Neuroendocrine Tumors

Introduction: Lung neuroendocrine tumors (NET) are classified as typical (TC) and atypical carcinoids (AT), according to their mitotic count and the presence of necrosis. However, a role for tumor side (right vs left) and location (central vs peripheric) has not been established so far.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: La Salvia A

Authors: La Salvia A, Trevisi E, Brizzi M, Espinosa Olarte P, Enguita A,

Keywords: Lung neuroendocrine tumors, tumor side (left versus right), tumor site (peripheric versus central), prognostic factors, survival,

#2733 Pancreatic Metastases Originating from Intestinal Neuroendocrine Tumours

Introduction: Pancreatic metastases are rare, accounting for 1 to 2% of pancreatic tumours. Data on pancreatic metastases of intestinal NETs are lacking.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Sadeh A, Librizzi D, Figiel J, Rodepeter F, Denzer U,

Keywords: Ki-67, prognosis, endoscopic ultrasound, intestinal NET, pancreatic metastases,

#2260 Carcinoid Heart Failure in a Metastatic Duodenal Neuroendocrine Tumor: A Challenging Case Report.

Introduction: Carcinoid heart disease (CHD) is a potenzial fatal cardiac manifestation, characterized by fibrous endocardial thickening involving right-sided heart valves. In 70% of cases, CHD occurs in advanced small bowel NETs with carcinoid syndrome (CS). Serotonin seems to play a main role. Early recognition and surgical intervention may improve the outcome of patients.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Brizzi M

Authors: Brizzi M, La Salvia A, Parisi F, Scagliotti G,

Keywords: Carcinoid Hearth Disease, Carcinoid syndrome, Surgery, somatostatin analogues,

#1578 Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors

Introduction: Everolimus represents a new treatment option for advanced pancreatic neuroendocrine tumors (pNETs).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Berardi R

Authors: Berardi R, Torniai M, Pusceddu S, Spada F, Brizzi M,

Keywords: pNET, dose intensity, targeted therapy, everolimus, cumulative dose,